<DOC>
	<DOCNO>NCT00603291</DOCNO>
	<brief_summary>The purpose study assess weight loss effect lorcaserin end 1 year treatment overweight obese patient Type II diabetes mellitus treat metformin , sulfonylurea ( SFU ) , either agent combination oral hypoglycemic agent .</brief_summary>
	<brief_title>BLOOM-DM : Behavioral Modification Lorcaserin Overweight Obesity Management Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>Overweight/obese men woman type 2 diabetes mellitus manage oral antihyperglycemic agent ( ) . Body mass index ( BMI ) 27 45 kg/m2 , inclusive . Ability complete 1 year study Pregnancy Use insulin form , exenatide ( Byetta ) pramlintide ( Symlin ) within 3 month prior screen History symptomatic heart valve disease Serious unstable current past medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>obesity</keyword>
	<keyword>weight loss</keyword>
	<keyword>lorcaserin</keyword>
	<keyword>APD356</keyword>
	<keyword>BLOOM-DM</keyword>
	<keyword>hypertension</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>sleep apnea</keyword>
	<keyword>glucose tolerance</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>Arena</keyword>
</DOC>